Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10652696 | 0.93 | TSHR (0.50) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL9222382 | 0.83 | NAAA (0.59) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL1563318 | 0.83 | TSHR (0.61) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL27626357 | 0.82 | TSHR (0.65) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL27646716 | 0.82 | TSHR (0.65) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL1069127 | 0.82 | TSHR (0.65) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL27646544 | 0.82 | TSHR (0.65) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL13266339 | 0.82 | TSHR (0.65) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL10954723 | 0.81 | TSHR (0.59) | TSHRNAAARAD52NPSR1EPHX1 | |
| SCHEMBL21638809 | 0.81 | TSHR (0.59) | TSHRNAAARAD52NPSR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021039799-A1 | CURABLE COMPOSITION | 株式会社日本触媒 | 2021-03-04 | — | — | WO | disclosed |